---
title: "Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3Ka inhibitor that decouples anti-tumor activity from hyperinsulinemia"
authors: "Varkaris A, Pazolli E, Gunaydin H, Wang Q, Pierce L, Boezio AA, DiPietro L, Frost A, Giordanetto F, Hamilton E P, Harris K, Holliday M, Hunter T L, Iskandar A, Ji Y, Lariv√©e A, LaRochelle J R, Lescarbeau A, Llambi F, Lormil B, Mader MM, Mar BG, Martin I, McLean TH, Michelsen K, Pechersky Y, Puente-Poushnejad E, Samadani R, Schram AM, Shortsleeves K, Swaminathan S, Tajmir S, Tan G, Tang Y, Valverde R, Wehrenberg B, Wilbur J, Williams BR, Zeng H, Walters WP, Wolf BB, Shaw DE, Bergstrom DA, Watters J, **Fraser JS**, Fortin PD, Kipp DR"
journal: Cancer Discovery
pub_date: "2023-11-02"
image: /static/img/pub/2023_varkaris.png
pmid: 37916956
#pdf: http://cdn.fraserlab.com/publications/2023_varkaris.pdf
---
